Genfit SA Sponsored ADR Stock News

Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), April 29, 2025 - GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announces the filing of its 2024 Universal Registration Document with the Autorité des marches financiers (AMF ; filing n° D.25-0331) and ...

Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), April 28, 2025 - GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced that Ipsen will be presenting data from its late-breaking abstract on elafibranor, highlighting favorable safety profile and sig...

Lille, France; Cambridge, MA; Zurich, Switzerland; April 24, 2025 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced annual financial results for the year ended December 31, 2024. A summary of the consolidated financial statements is included below.

Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), March 20, 2025 - GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases (the “Company”), is pleased to announce the successful completion of its royalty financing transaction with HealthCare Royalty (“HCRx”) and the r...

Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), March 10, 2025 - GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases (the “Company”), today announces the results of the bondholders' vote at the general meeting of the 2025 OCEANEs holders which took place this Mo...

Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), February 27, 2025 - GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced its cash position as of December 31, 2024 and revenues for 2024

Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), February 21, 2025 - GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announces that it has signed Put Option Agreements with 2025 OCEANEs holders and the convening of the general meeting of the 2025 OCEAN...

Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), February 14, 2025 - GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced the amendment of the final terms of the 2025 OCEANEs repurchase proposal and the consent fee that would be paid to the holder...